DBV Technologies reported $17.5M in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 178.32M 11.98M Sep/2026
Alnylam Pharmaceuticals USD 1.08B 172.17M Sep/2026
Amarin USD 126.83M 477K Dec/2025
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
BioMarin Pharmaceutical USD 1.08B 15.31M Sep/2026
DBV Technologies USD 17.5M 2.4M Sep/2026
Halozyme Therapeutics USD 518.59M 65.26M Sep/2026
Incyte USD 1.24B 111.82M Sep/2026
Insmed USD 259.27M 43.94M Sep/2026
Ionis Pharmaceuticals USD 88M 29.15M Sep/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
PTC Therapeutics USD 239.04M 19.12M Jun/2026
Sarepta Therapeutics USD 385.98M 7.82M Sep/2026
Ultragenyx Pharmaceutical USD 200M 140M Jun/2026
United Therapeutics USD 348.6M 38.3M Sep/2026